Umoja Biopharma will pair its so-called VivoVec particles with Lupagen’s Side CAR-T delivery system to target certain cancers, the companies said Monday.

Cerevance is targeting these fluctuations with a planned Phase II/III trial of its investigational compound CVN424, CMO Jordan Dubow says. The Boston-based biotech plans to initiate the study in the first quarter of 2023, testing CVN424 as an adjunctive therapy to levodopa, he adds.

Elicio Therapeutics published data on the preprint server, bioRxiv, describing preclinical research on its cancer vaccine that shows a lot of promise.

Swedish biotech Calliditas is going all-in when it comes to firsts: After getting the first drug specifically approved for immunoglobulin A (IgA) nephropathy last year, it’s now running the first educational campaign for the disease amid the first-ever IgAN Awareness Day.

Life sciences VC firm Flagship Pioneering has unveiled a new company called Sonata Therapeutics to develop cell signaling therapies for oncology, fibrosis and autoimmune disorders.

Treatment with 200 µg of LSD yielded quick and significant improvements in symptoms of anxiety in a phase II trial, MindMed announced.

When Mike Catelani seeks to identify the objectives and career milestones that have helped to advance him into the ranks of Bay Area biotech CFOs, he mentions that although he had a deep interest in biology during his high school years, upon entering college he decided to swap out a biology curriculum for an accounting one.

The thin-film freezing specialist reports positive safety and pharmacokinetic data coming out of the Phase I trial of its niclosamide inhalation powder.